Soliris Indication:

For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Soliris Mechanism Of Action:

Soliris, the active ingredient in Soliris, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Soliris inhibits terminal complement mediated intravascular hemolysis in PNH patients. A genetic mutation in PNH patients leads to the generation of populations of abnormal RBCs (known as PNH cells) that are deficient in terminal complement inhibitors, rendering PNH RBCs sensitive to persistent terminal complement-mediated destruction. The destruction and loss of these PNH cells (intravascular hemolysis) results in low RBC counts (anemia), and also fatigue, difficulty in functioning, pain, dark urine, shortness of breath, and blood clots.

Soliris Drug Interactions:

Not Available

Soliris Food Interactions:

Not Available

Soliris Generic Name:


  • 5G1.1

Drug Type:

Biotech; Approved; Investigational


Not Available

Toxicity (Overdose):

Not Available

Protein Binding:

Not Available


Not Available

Half Life:

272 ± 82 hrs (mean ± SD)

Dosage Forms of Soliris:

Solution Intravenous drip

Chemical IUPAC Name:

Not Available

Organisms Affected:

Humans and other mammals

Soliris to general, pharmacology

General, pharmacology..